Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health Inc (NQ: JAGX )

1.060 +0.010 (+0.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 105,528
Open 1.070
Bid (Size) 1.050 (26)
Ask (Size) 1.100 (111)
Prev. Close 1.050
Today's Range 1.050 - 1.070
52wk Range 0.9501 - 30.86
Shares Outstanding 171,350,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
Via ACCESSWIRE
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
Via ACCESSWIRE

Performance

YTD
-88.32%
-88.32%
1 Month
-19.08%
-19.08%
3 Month
-5.36%
-5.36%
6 Month
-94.43%
-94.43%
1 Year
-94.48%
-94.48%

More News

Read More
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
Via ACCESSWIRE
Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
Via ACCESSWIRE
New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones
Via ACCESSWIRE
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Via ACCESSWIRE
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Via ACCESSWIRE
Why Jaguar Health (JAGX) Stock Is Down 15%
Via Benzinga
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
Via ACCESSWIRE
Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and
Via ACCESSWIRE
Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
Via ACCESSWIRE
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
Via ACCESSWIRE
Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference
Via ACCESSWIRE
Jaguar Health Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
Via ACCESSWIRE
Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care
Via ACCESSWIRE
Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference
Via ACCESSWIRE
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Via ACCESSWIRE
Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
Via ACCESSWIRE
JAGX Stock Earnings: Jaguar Health Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
Via ACCESSWIRE
Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningful
Via ACCESSWIRE
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
Via ACCESSWIRE
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.